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Currentcurativestrategiesforprostatecancerarerestrictedtotheprimarytumour,andtheeﬀectoftreatmentstocontrolmetastatic
disease is not sustained. Therefore, the application of gene therapy to prostate cancer is an attractive alternative. Baculoviruses are
highly restricted insect viruses, which can enter, but not replicate in mammalian cells. Baculoviruses can incorporate large amounts
of extra genetic material, and will express transgenes in mammalian cells when under the control of a mammalian or strong viral
promoter. Successful gene delivery has been achieved both in vitro and in vivo and into both dividing and nondividing cells, which
is important since prostate cancers divide relatively slowly. In addition, the envelope protein gp64 is suﬃciently mutable to allow
targeted transduction of particular cell types. In this review, the advantages of using baculoviruses for prostate cancer gene therapy
are explored, and the mechanisms of viral entry and transgene expression are described.
WHY GENE THERAPY FOR PROSTATE CANCER?
The case for new therapies in prostate cancer is partic-
ularly strong, given the frequency of the disease in a west-
ern population that is increasingly elderly (Dijkman and
Debruyne [1]). Conventional therapies, such as surgery
and radiotherapy can be eﬀective if early stage disease is
detected and targeted for therapy, a strategy employed on
a wide scale in the USA (Bubolz et al [2]; Pirtskhalaishvili
et al [3]). Even in the later stages of the disease, interven-
tiontoblockthenecessarysupplyofandrogensiseﬀective
in the short term, although resistant tumours develop rel-
atively rapidly, within 1–2 years (BJ Feldman and B Feld-
man [4]). Cytotoxic chemical therapies are rarely eﬀec-
tive. Thus a therapeutic strategy, in which the genetic na-
ture of the prostate tumour is turned against the cancer
is very attractive. The mantra of successful gene therapy
for prostate cancer has been repeated many times since
the earliest reports of successful gene transfer were pub-
lished (reviewed in Roth and Grammer [5]). In this re-
spect, the prostate is both a good and bad target for spe-
ciﬁc therapy. On the credit side, the prostate itself, like
mostsecretoryorgans,displaysradicallydiﬀerentpatterns
of gene expression from most other organs, and many
of these “tissue-speciﬁc” products are retained in the tu-
mours. Tissue speciﬁcity can be turned against the tu-
mour, both at the cell surface level (attachment of ther-
apeutic agents) and at the transcriptional level to direct
expression of therapeutic genes. The range of candidates
has been covered in an earlier review (Maitland [6]). In
addition, there are a number of tumour associated anti-
gens, whose expression is upregulated in prostate tu-
mours. It is in this respect that prostate tumours remain a
poor candidate for strictly gene-based therapy. Firstly, the
range of tumour antigens is small, but increasing in view
of recent stimulation of research in this area (Liu [7]; Luo
et al [8]; Ornstein et al [9]). Secondly, the natural history
of the disease is relatively poorly understood, in compari-
son with breast cancer, a disease of similar incidence and
mortality. Prostate tumours display genetic and antigenic
heterogeneity (Macintosh et al [10]), and the ability to ac-
curately predict the course of the disease (and therefore to
identify patients for gene therapy regimes) remains rather
primitive relative to breast cancers (Van’t Veer and De
Jong [11]), despite the application of gene array technol-
ogy (Dhanasekaran et al [12]). Finally, prostate tumours
display an ability to shift phenotype, probably by selec-
tively activating or inactivating gene expression, for ex-
ample, in the development of androgen-independent dis-
ease (Karan et al [13]; Tso et al [14]) and the inactivation
at the transcriptional level of genes encoding carcinogen-
inactivating enzymes (Lee et al [15]). This would seem to
be the ideal mechanism to inactivate the expression of ex-
ogenous therapeutic genes.
It is also likely, given the genetic and clinical hetero-
geneity of prostate cancers, that a range or even a combi-
nation of gene therapy strategies with conventional treat-
mentswillbeneededtoachieveasubstantialeﬀect.Thisis
particularly true with viral vectors, where an existing im-
mune memory against human viruses (eg, adenoviruses)80 Lindsay Stanbridge et al 2003:2 (2003)
could preclude their use in certain cases. Indeed, to opti-
mise the therapeutic eﬀects, simultaneous infection with
a “cocktail” of therapeutic viruses (to overcome the ini-
tial tumour heterogeneity) or sequential inoculation with
diﬀerent virus types (to escape either preexisting or
therapy-induced antiviral immunity) may be necessary.
However, neither strategy will be clinically feasible un-
less all unacceptable risks of side eﬀects can be elimi-
nated. Lastly, and perhaps most importantly, the method
of inoculation and dosage has to be optimised. For ex-
ample, should the primary target for gene therapy be or-
gan conﬁned disease, where the conventional therapeutic
strategies are moderately eﬀective, or against metastatic
disease?
So can baculoviruses provide an alternative means
of delivering therapeutic genes into organ conﬁned and
metastatic prostate cancer?
WHAT ARE BACULOVIRUSES?
It is perhaps surprising that there are more than 500
diﬀerent types of baculoviruses (Martignoni and Iwai
[16]). They are widespread pathogens of insects and in-
vertebrates, ranging from shrimps to moths and butter-
ﬂies. However, the most studied types are those which
causediseaseincommoninsectpests.Researchwasdriven
initially by the intention to use them as a biological insec-
ticide (Ignoﬀo[ 17, 18]; Martignoni [19]). The individ-
ual baculoviral strains have a limited host range, which is
usually restricted to one species [20, 21]. Pioneering stud-
ies at Texas A&M University, where the eﬀects of the Au-
tographa californica multiple nuclear polyhedrosis virus
(AcMNPV) on the fall army worm were ﬁrst studied in
moleculardetail.MNPV’sareasubgroupofbaculoviruses
that produce large polyhedral occlusion bodies as part of
the viral life cycle [21]. Polyhedrin is a 246-amino acid
(29kd) protein, which forms a hard polyhedral protein
m a t r i xo fb e t w e e n0 . 1 5t o1 5µmi nw h i c hB vn u c l e o c a p -
sids, surrounded by a single unit membrane, are embed-
ded. This provides the ultimate protection in the wild.
These polyhedra, are however susceptible to the alkaline
environment in the midgut of the host insect, releasing
infectious virus, into susceptible host cells (reviewed in
Harrap and Longworth [22]). Polyhedra can be visualised
as refractive crystals in the nucleus of infected insect cells
under light microscopy. The polyhedrin embedded oc-
cluded virus (OV) is formed very late in the baculoviral
life cycle, in contrast to the budded virus (BuV) formed
earlier in the infectious life cycle [20]. Both OV and
BuV are rod shaped with a supercoiled dsDNA genome
of 80–200kilobasepairs (approximately 134kbp in AcM-
NPV), which is condensed into a nucleoprotein core with
proteins p39 and p87 [20, 23]. As a result of budding
out through the cell plasma membrane, BuV acquire a
loosely ﬁtting viral envelope which has peplomers pro-
truding around one end [20]. These peplomers are com-
prised of the major envelope glycoprotein gp64, which
is responsible for cell to cell spread and secondary viral
infection. In contrast, AcMNPVOV consists of multi-
ple nucleocapsids surrounded by a de novo synthesised
viral envelope which does not display gp64 peplomers
[20]. This led to the development of the virus as a po-
tential gene cloning vector, exploiting the readily avail-
able cell lines from the midgut of the moth, and the
ability to recombine into the viral genome by cotrans-
fection of intact viral DNA with a segment of the vi-
ral genome containing an exogenous gene, normally un-
der the control of one of the very strong late promot-
ers such as that for the polyhedrin gene. A diagrammatic
version of the baculoviral infectious process is shown in
Figure 1.
Many of the 151 recognised open reading frames
(Genbank number NC 001623) encode proteins of as
yet unknown function. However, like many larger DNA
viruses, the Bv genome does contain a large number of
proteins whose main function is to subvert both host cell
and host organism defences. In many cases these are ho-
mologues of host cell proteins such as ubiquitin, PCNA,
and viral DNA polymerase/RNA polymerase components
(reviewed in Ayres et al [24] ;K o o la n dV l a k[ 25]). There
are also homologues of growth factors, intracellular sig-
nalling molecules, and perhaps most notably, a unique
apoptosis suppressor p35, which is functional in both
insect and human cells (Hsu et al [26]; Resnicoﬀ et al
[27]; Robertson et al [28]). The genomic location of some
of these open reading frames is indicated in Figure 2.
Clearly, the expression of some or all of these Bv func-
tions, which are suﬃciently closely related to human ho-
mologues, would be undesirable in a human gene therapy
vector, particularly one designed to kill cancer cells.
GENERATION OF RECOMBINANT BACULOVIRUSES
When the ﬁrst baculoviral protein expression vectors
were generated, the selection system was based on the loss
of the polyhedrin gene, by recombination from a transfer
plasmid, which disrupted the PH coding sequence. This
resulted in infected cells lacking the characteristic occlu-
sion bodies, composed of enveloped nucleocapsids em-
bedded in a polyhedrin matrix. In practice it took some
time to become experienced in identifying nonoccluded
viral plaques, and the recombinants were frequently con-
taminatedbynonrecombinantwild-typevirus,whichina
large scale culture could outgrow the recombinants, par-
ticularly when the recombinant protein expressed had cy-
topathic properties.
More recent developments have used cotransfection
of multiply-deleted viral genomes (eg, the commercially
available BacVector 1000series) together with the transfer
vector (generated in a bacterial plasmid) which contains
recombination sequences, normally from the nonessen-
tial polyhedrin gene. Capacity for recombinant inserts is
at least 40kbp in this rod form virus, although in practice
this could be diﬃcult to maintain in the transfer vector.2003:2 (2003) Baculoviruses as Vectors for Gene Therapy against Human Prostate Cancer 81
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Figure 1. Baculovirus infection of insect and mammalian cells. (1) Budded virus (BuV) particles interact with the mammalian cell
surface via the surface gp64 protein in both insect and mammalian cells (described in the text). The occluded virus (OV) polyhedrin
matrix is digested in the insect midgut lumen releasing occlusion derived virions (ODV), which consist of multiple nucleocapsids
surrounded by a membrane. (2) ODV particles fuse with the microvilli membranes of midgut epithelial cells, releasing nucleocapsids
intothecytoplasm.(2a)BuVparticlesaretakenupintoendosomesfromwhichtheyescapebyendosomeacidiﬁcationandmembrane
fusion (2b). (3) Virus particles are transported to the nucleus where they bind the nuclear pores and whole virions containing the
genomeareactivelytransportedthroughtheporesintothenucleus.ViralDNAisreleasedfromthenucleocapsid.(4)Ininsectcells,the
baculoviralgenesaretranscribedwhereasinmammaliancells,onlygenesunderthecontrolofamammalianpromoteraretranscribed.
(5) In insect cells, viral DNA is replicated and packaged into nucleocapsids. During the late phase of infection, nucleocapsids exit the
nucleus and bud from the cell membrane to form BuV. During the very late stage of infection, nucleocapsids remain in the nucleus
where they are enveloped and embedded in a polyhedrin matrix to produce OV. In mammalian cells, virus replication does not take
place and no progeny virus is produced.82 Lindsay Stanbridge et al 2003:2 (2003)
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Figure 2. Genomic map of Bv (AcNPV) genome. Some signiﬁ-
cant open reading frames are indicated. Detail is the polyhedrin
(PH) cloning sites for recombinants.
Recombinant viral yields from the BacVector (Novagen
Inc, Madison, Wis, USA) system are high and wild-type
viral yields are virtually eliminated, by use of the “triple
cut” system, which uses Bv DNA in which the PH gene
has been disrupted by insertion of the β gal gene, lead-
ing to blue nonrecombinant Bv plaques in the presence
of Xgal indicator. The second and more important step
is the introduction of a site for the rare cutting restric-
tionendonucleaseBsu36Iwithintheessential(forreplica-
tion) Bv gene ORF1629. Further Bsu36I sites are located
in the βgal and in the other Bv ORF ﬂanking PH ORF:
ORF603. The complementing ORF1629 protein is sup-
plied by the recombination transfer vector, and the triple
cut Bv DNA cannot produce viable virus without addi-
tion of the ORF1629 (see Figure 2). Thus the production
of wild-type virus and isolation of recombinants is not a
serious problem in this system.
TherecentdevelopmentoftheBACtoBACvectorsys-
tem (Invitrogen), in which the entire Bv genome has been
cloned into a bacterial artiﬁcial chromosome, enables the
recombination to be carried out with higher eﬃciency
and control in bacteria. This results in higher yields and
more rapid recombinant generation (Luckow et al [29])
as with similar adenoviral systems (eg, AdEasy from Q-
Biogene, Illkirch, France).
ADVANTAGES OF BACULOVIRUSES AS A GENE
THERAPY VECTOR
Firstly,Bvisarodform,andlimitationstotheamount
of extra genetic information inserted into the recombi-
nants such as those imposed by the deﬁned adenovirus
capsid are not appropriate. It has been estimated that
standard Bv, without further deletions, can accommo-
date more than 38kilobases of extra genetic information
(Cheshenko et al [30]).
B a c u l o v i r u sd o e sn o te x p r e s si t so w ng e n e so rr e p l i -
cate in human cells. As long ago as 1983, Tjia et al showed
that there was an absence of Bv gene transcription in in-
fected HeLa cells (Tjia et al [31]). In another study, no
detectable expression from the polyhedrin promoter was
demonstrated in Huh7 cells (Hofmann et al [32]). In a re-
cent study in our laboratory (A. Jones et al, manuscript in
preparation), using the most sensitive methods currently
available (ie, RT-PCR) the expression of a number of the
potentially pathogenic Bv genes was assessed after suc-
cessful infection of human and insect cells. Whereas the
appropriate PCR products were detected in the infected
insect cells, they were absent in Bv infected human cells,
which did however express a marker gene under human
promoter control. Even extending PCR cycles up to 40
did not produce a Bv gene product in the human cells.
These results are not entirely unexpected, particularly as
thelateandverylateBvgenesaretranscribedbyanalpha-
amanatin resistant RNA polymerase (BvAARP) (Huh and
Weaver [33]), which is at least partly encoded within the
Bv genome (Passarelli et al [34]). In addition, the abso-
lute requirement for BvAARP mediated expression of the
late structural proteins in the assembly and production of
progeny virus provides another “ﬁre wall” to prevent the
generation of replicating virus in human cells and tissues.
Mammalian viruses, and in particular those currently
employed in gene therapy trials are critically dependent
on host cell functions to complete their life cycle. The vi-
ralproteinscaninteractwithhostcellproteinsandnucleic
acids, often perturbing the host cell cycle and viability. As
theBvgenes,whichperformthesefunctionsininsectcells
are not expressed in mammalian cells, Bv infection is un-
likely to aﬀect the target cells. This is particularly impor-
tant for gene therapy protocols involving correction of a
cell gene defect rather than killing of the target cells, as
proposed for cancer gene therapy. Encouragingly, Bv in-
fection of primary pancreatic islet β-cells did not aﬀect
normal cellular calcium responses to glucose, which has
important implications for gene therapy of diabetes (Ma
et al [35]).
Baculovirus does not recombine with preexisting ge-
netic material: a potential drawback of the mammalian
viruses, where endogenous virus is widespread in the hu-
man population, and the potential for interspeciﬁc re-
combination could produce new replication-competent
viruses with a new pathogenicity, or cell trophism. Bac-
ulovirus also cannot “help” replication of endogenous
viruses in humans, such as adenovirus and adeno-
associated viruses.
The BV gp64 envelope protein is suﬃciently muta-
ble to allow the rapid insertion of new and more spe-
ciﬁc attachment sequences, much more readily than those
described recently for AdV ﬁbre protein (Krasnykh et al
[36]), without perturbing its function as the principal at-
tachment protein. This technique has already been ex-
ploited to produce antigen display in the membrane of Bv
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and insect cells, a mosaic envelope with wild-type and re-
combinant gp64 is required, which cuts down on infec-
tion eﬃciency in both cell types. However, eﬀective retar-
geting has already been demonstrated.
In contrast to many of the other therapeutic viruses,
Bv can be grown in serum-free culture media and in large
quantities. In our hands, the viruses are completely stable
and their production can be readily scaled up to indus-
trial levels (currently 2–3litres can be cultured without
loss of viral viability or selection of mutant Bv). The in-
dustrial scale culture of Bv is also possible in serum-free
culture conditions, which removes the potential hazard of
serum contamination of the therapeutic agent with viral
andprionagentsfromthedonatinganimal.Thereishow-
ever a tendency in high level production for the virus par-
ticles (like many recombinant enveloped viruses) to ag-
gregate, which could limit the dosages applied clinically.
Lastly, for in vivo use, there is no preexisting immune
response against Bv in humans (a common problem
associated with all human viral vectors, including ade-
noviruses). However a complement response has been
demonstrated, although a number of investigations have
produced inhibition strategies in animal models which
prevent rapid elimination ofintravenous injected Bv.This
is dealt with later in more detail.
IN VITRO TRANSDUCTION OF MAMMALIAN CELL
LINES WITH BACULOVIRAL VECTORS
Expressionofatransgeneunderthecontrolofamam-
malian promoter in human cells following transduction
with a recombinant baculovirus was ﬁrst shown by Hof-
mann et al in 1995 (Hofmann et al [32]) and Boyce and
Bucher in 1996 (Boyce and Bucher [38]). These stud-
ies and others have reported that hepatic cells, such as
the human liver tumour cell lines HepG2 and Huh7, are
generally the most susceptible mammalian cell type to
infection by baculoviruses in vitro (Sandig et al [39]).
Following infection with a recombinant baculovirus at
an MOI of 100pfu per cell, approximately 25–50% of
HepG2 cells were shown to be positive for LacZ trans-
gene expression whereas transduction of COS-7 (mon-
key kidney), A549 (human lung), and 293 (human kid-
ney) cells was 10 to 100-fold less eﬃcient (Boyce and
Bucher [38]). However, there remains some controversy
about the best target for Bv transduction in compar-
ative tests of Cos-1 (SV40-transformed green monkey
kidney epithelial cells), T47-D (mammary ductal carci-
noma), A549, CHO (Chinese hamster ovary), HeLa (cer-
vical carcinoma), HaCaT (keratinocyte), NIH 3T3 (ﬁ-
broblasts), and COS-7 (Hofmann et al [32]; Sarkis et al
[40]). The human osteogenic sarcoma cell line SAOS-2
cells expressed a baculoviral-mediated LacZ transgene at
levels almost 20-times greater than in HepG2 cells (Song
andBoyce[41]).Ourownstudiesshowthatboth293(hu-
man embryonic kidney) and PC3 (prostate cancer) cells
can be transduced with approximately equal eﬃciency
(a)
(b)
Figure 3. Infection of PC3 prostate cancer cells with a human-
ised Bv expressing EGFP from a hybrid CAG promoter. Phase
image of infected cells (a) after 24hours indicates conﬂuency
of cultures while ﬂuorescent image (b) conﬁrms high infectiv-
ity (at > 100particles/cell) of the tumour cells. After a further
24–48hours more than 90% of the tumour cells express EGFP.
(25–50%) when infected with a CAG-EGFP baculovirus
at an MOI of >100 (A. Jones, unpublished results, 2000).
A typical result is shown in Figure 3.
INFECTION OF PRIMARY CELL CULTURES
WITH BACULOVIRUSES
Keratinocytesandbonemarrowﬁbroblastsareamong
the primary human cell types to be successfully trans-
duced with a baculoviral vector (Condreay et al [42]).
Approximately 70% of primary hepatocytes were shown
to express β-galactosidase following transduction with84 Lindsay Stanbridge et al 2003:2 (2003)
an RSV-LacZ baculovirus at an MOI of 430 (Boyce and
Bucher [38]). A much lower MOI of 25 was reportedly
suﬃcient to transduce approximately 30% of undiﬀer-
entiated primary human neural progenitor cells and ap-
proximately 55% of diﬀerentiated primary human neu-
ral cells with a CMV-EGFP baculovirus (Sarkis et al
[40]).
BACULOVIRUS INFECTION OF EPITHELIAL CELLS
IS INDEPENDENT OF THE CELL CYCLE
One unusual feature of prostate cancers is that the
tumour cells multiply at an apparently slower rate than
other cancers. Recombinant baculoviruses are however
able to transduce both nondividing and actively dividing
cells. For example, a G1/S arrested epithelial pig kidney
cell line was infected as eﬃciently as dividing cells of the
same type (van Loo et al [43]).
EFFICIENCY OF BACULOVIRAL-MEDIATED GENE
TRANSFER IN VITRO
At a MOI of 10, comparing both levels of transgene
expression and percentage of cells expressing the trans-
gene, baculoviruses are comparable to lipofectamine and
calcium phosphate precipitation as gene delivery vehicles
for Huh7 cells (Hofmann et al [32]). At an MOI of 100,
baculoviruses are much more eﬃcient than both nonviral
methods. A comparison with adenoviruses shows that at
anMOIofboth10and100,transductionbyabaculovirus
vectorresultsinhigherβ-galactosidaseactivity,thanwhen
the same expression cassette was transduced by an aden-
ovirus. However, the overall percentage of cells expressing
the LacZ gene following transduction with the adenoviral
vector was approximately twice that obtained when trans-
duced with the baculovirus vector (Hofmann et al [32]).
The number of primary pancreatic islet β-cells express-
ing GFP following transduction with a CMV-EGFP bac-
ulovirus were comparable to that reported for lentiviral
a n da d e n o v i r a lv e c t o r s( M ae ta l[ 35]).
IN VIVO TRANSDUCTION OF MAMMALIAN CELLS
WITH A BACULOVIRAL VECTOR
Initial attempts to use baculovirus vectors as gene de-
livery vehicles in vivo failed because the virus particles
were inactivated by the complement immune response
(Sandig et al [39]). However, in vivo gene delivery pro-
tocols that bypass the complement system have shown
encouraging results. A CMV-LacZ baculovirus was ad-
ministered to rabbit carotid arteries in vivo via a silas-
tic collar ﬁtted directly onto the artery (to sequester the
Bv from exposure to blood). This resulted in expression
of β-galactosidase in a comparable number of cells as
achieved by administration with a CMV-LacZ adenovirus
(Airenneetal[44]).DirectinjectionofaCMV-EGFPbac-
ulovirus into rat and mouse brain striatum resulted in
transduction of neural cells in vivo, within a millimetre
of the injection site (Sarkis et al [40]). The brain may
represent a privileged site for Bv infection as the com-
plement response did not abrogate transduction. In vivo
gene transfer by direct injection into mouse skeletal mus-
cle was achieved in the presence of complement with a
baculoviral vector pseudotyped with VSVG, which has
been shown to protect viral vectors from complement
(Pieroni et al [45]).
MECHANISM OF MAMMALIAN CELL
TRANSDUCTION BY BACULOVIRAL VECTORS
Forinfectionofbothinsectandmammaliancells,bac-
uloviruses are required to interact with the cell surface
via its surface gp64 protein (Heﬀeron et al [46]; Tani et
al [47]). It has been suggested that the cell binding and
uptake mechanism may be via a speciﬁc receptor since
permissiveness varies widely between diﬀerent cell types.
For example, the rat hepatoma cell line H35, may be
nonpermissive (van Loo et al [43]). This could reﬂect dif-
ferences in receptor expression levels but to date, no such
receptor has been identiﬁed. The asialoglycoprotein re-
ceptor was initially suggested as a candidate but it was
subsequently shown that a cell line expressing the cloned
receptor did not show signiﬁcant viral uptake (Hofmann
et al [32]) and van Loo et al demonstrated eﬃcient trans-
duction of an epithelial pig kidney cell line (Pk1) that did
not express this receptor (van Loo et al [43]). Electrostatic
interactions between the viral and cellular membranes
have been shown to be critical for baculovirus transduc-
tion, probably via negatively charged cell surface epitopes
such as heparan sulphate (Duisit et al [48]).
At high MOI, Bv particles can be seen to completely
coat mammalian cells. For example, in Figure 4a,a3 T 3
cell has been infected at 4◦Cw i t ha ne x c e s so fB v ,a n dt h e
extracellular gp64 stained with a monoclonal antibody.
The ﬂuorescent ring follows the murine cell membrane,
indicating high eﬃciency attachment. A similar result is
obtained with prostate epithelial cells (PNT1A), which
contract after 4◦Ce x p o s u r e .
Evidence that baculoviruses are taken up by endo-
cytosis has been provided by (i) electron microscopy of
CHO cells (Condreay et al [42]), and (ii) the observed re-
duction of virus transduction in the presence of chloro-
quine (Boyce and Bucher [38]; Hofmann et al [32]). As
with other viruses (eg, inﬂuenza and adenoviruses), en-
dosome acidiﬁcation is required for release of the bac-
uloviruses from the endocytotic pathway into the cyto-
plasm and subsequent transport, probably involving actin
ﬁlaments, to the nucleus (Blissard and Wenz [49]; Boyce
and Bucher [38]; van Loo et al [43]). Unlike many other
viruses, both nucleocapsids and viral genomes can be de-
tected inside the nucleus of infected cells (van Loo et al
[43]). Electron microscopy images indicate that the bac-
uloviralnucleocapsidsdockontonuclearporesininfected
cells, before being transported through into the nucleus.2003:2 (2003) Baculoviruses as Vectors for Gene Therapy against Human Prostate Cancer 85
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Figure 4.SpeciﬁcattachmentofrecombinantBvtomammalian
cells. 3T3 cells (a) and prostate epithelial cells PNT1A (b) were
infectedwith> 100particles/cellwithahumanisedBvfor1hour
at 4◦C to permit attachment but not penetration. The cells were
thenﬁxedandstainedwithanantibodyagainsttheBvgp64pro-
tein.Controlsareshownintheinserts(novirusinfectionandno
primary antibody). Note the even coating of the 3T3 cells and
the patchy but strong staining of the PNT1A cells.
This is observed in mitotic and nonmitotic cells. There-
fore, it is likely that the capsids are transported through
nuclear pores rather than taken up during mitosis (van
Loo et al [43]).
The lack of transgene expression in cell lines less per-
missive to baculoviral transduction is more likely to be
due to a block at the level of viral uncoating or tran-
scription rather than virus entry, since viral DNA can
be detected at approximately equal amounts in highly
permissive (HepG2) and less permissive (Sk-Hep-1) cells
24hours postinfection (Boyce and Bucher [38]). Also,
RNA transcribed from a mammalian promoter-gene cas-
sette can only be detected in transduced HepG2 cells and
not in Sk-Hep-1 cells (Boyce and Bucher [38]). Barsoum
et al (Barsoum et al [50]) demonstrated that in the highly
permissive HepG2 cells, baculovirus DNA was present in
the nucleus 24hours after infection and that the DNA
was packaged into chromatin as determined by digestion
with staphylococcal nuclease. Conversely, in HeLa cells,
DNA was not detected in the nucleus, and EM analysis
supports the theory that much of the virus infected into
HeLa cells is trapped inside intracellular vesicles. Eﬀective
escape from endosomes is thus a critical step in baculovi-
ral transduction of mammalian cells.
BACULOVIRUS-MEDIATED TRANSGENE
EXPRESSION IN MAMMALIAN CELLS
The onset of transgene expression has been shown as
earlyas6hoursposttransductionwitharecombinantbac-
ulovirus and can reach peak expression levels after 12 to
24hours (Boyce and Bucher [38]). Expression has consis-
tently been shown to persist at approximately peak levels
for at least a week both in vitro (Hofmann et al [32]; Ma
et al [35]) and in vivo (Airenne et al [44]; Haeseleer et
al [51]; Sarkis et al [40]). In the absence of complement,
transgene expression has been detected for up to 178days
in vivo (Pieroni et al [45]).
It is possible to generate stable cell lines from cultured
cells by selection of baculovirus transduced cells with
G418 when a neomycin resistance cassette is included in
the baculoviral transfer vector (Condreay et al [42]). Fol-
lowing infection of CHO cells at an MOI of 1pfu per cell,
approximately 1–2% of cells that had been transduced by
the virus went on to form G418 resistant colonies (Con-
dreay et al [42]). This is relatively ineﬃcient and is even
less likely to occur in vivo since there will be no selec-
tive pressure for integration to become a selective advan-
tage. Further analysis revealed that fragments of the bac-
uloviral genome ranging in size from 5 to 18kb had inte-
grated into the CHO cell genome (Merrihew et al [52]).
T h eb r e a k p o i n t si nt h ev i r u sg e n o m ew e r er a n d o m l yl o -
cated and with little homology between baculovirus and
CHO cell DNA at recombination sites, suggests a mecha-
nism of illegitimate recombination (Merrihew et al [52]).
If stable integration is required for a particular gene ther-
apyprotocol,sitespeciﬁcintegration should besafersince
the risk of insertional inactivation is much lower. This has
beenapproachedbycreationofahybridbaculovirus-AAV
(adeno-associated virus) vector resulting in Chromosome
19-speciﬁc integration in mammalian cells (Palombo et al
[53]).
HDAC inhibitors such as trichostatin A (TCA) and
butyrate have been shown to increase expression levels of
a baculovirus encoded mammalian transgene in a wide
variety of cultured cells including HeLa, Huh7, CHO,
COS7, and 293 in addition to primary cultures of hu-
man keratinocytes, bone marrow ﬁbroblasts, and neural86 Lindsay Stanbridge et al 2003:2 (2003)
cells (Airenne et al [44] ;C o n d r e a ye ta l[ 42]; Sarkis et al
[40]). Although probably not feasible to use for in vivo
gene therapy protocols, this could be applied to ex vivo
gene transfer systems.
ENGINEERING PROSTATE SPECIFICITY FOR
THERAPEUTIC GENE EXPRESSION IN Bv VECTORS
Although most studies of baculoviral-mediated gene
transfer to date have employed the use of strong, virus
derived promoters such as the CMV immediate early pro-
moter or RSV, expression from a tissue speciﬁc promoter
has also been demonstrated. The α-fetoprotein (AFP)
promoter was successfully used to direct expression of a
transgene speciﬁcally in AFP-expressing hepatic cells in
vitro(Parketal[54]).Thishasimportantimplicationsfor
gene therapy in vivo, demonstrating that transcriptional
targeting is a possibility for baculoviral gene therapy.
There are now numerous reports of successful use of
prostate-speciﬁc gene promoters incorporated into other
gene therapy vectors that have been tested in vivo, includ-
ing a PSA promoter-based lentivirus (Yu et al [55]), a PSA
promoter-based adenovirus (Li et al [56]), an osteocal-
cin promoter-based adenovirus (Matsubara et al [57]),
a probasin promoter-based adenovirus (Lowe et al [58];
Martiniello-Wilks et al [59]) (Xie et al [60]), and a hu-
man kallikrein 2 promoter-based adenovirus (Xie et al
[61]).
In addition, a number of “prostate-speciﬁc” promot-
ers have been tested for speciﬁcity after transfection into
cultured cells. Amongst the most promising are PSMA
(O’Keefe et al [62]), DD3 (Verhaegh et al [63]), PART-1
(Lin et al [64]), prostate transglutaminase (Dubbink et al
[65]), prostatic acid phosphatase (Zelivianski et al [66]),
and NKX3.1 (Prescott et al [67]; Xu et al [68]). There are
no good reasons to suspect that their enhanced activity in
prostatecellswillbecompromisedinanywaybyinsertion
into Bv vectors.
Also, prostate tumour cells in vitro are highly suscep-
tible to Bv infection, as demonstrated not only by the at-
tachment results shown in Figure 4, but also conﬁrmed
by the result shown in Figure 3, where the strong hybrid
CAG promoter has been used to drive EGFP expression
in PC3 prostatic carcinoma cells, after transduction by a
recombinant Bv.
Theadditional genetic capacity of therecombinantBv
should also allow coexpression of transcriptional mod-
ulatory genes. The best example of this might be an-
drogen receptor, whose activity is frequently depressed
in androgen insensitive tumours. In addition, many of
the prostate-speciﬁc gene promoters are positively regu-
lated by male sex hormnes, but could be inactive (mu-
tated) or transcriptionally inactivated in hormone insen-
sitive metastatic tumours. Therefore, coexpression of an
intact or partial androgen receptor to stimulate expres-
sion from the androgen responsive promoters (Suzuki et
al [69]) should be possible.
BACULOVIRUS VECTOR MODIFICATIONS
FOR GENE THERAPY
Attachment targeting of baculoviruses to speciﬁc re-
ceptorsonthesurfaceofmammaliancellscanbeachieved
by inserting attachment modifying sequences into the
gp64 membrane protein, for example, insertion of a func-
tional single chain antibody fragment speciﬁc for car-
cinoembryonic antigen (CEA) or two copies of a syn-
thetic IgG binding domain of protein A (Ojala et al [70]).
According to one study, addition of a modiﬁed gp64 cod-
ing region into the baculoviral genome resulted in an ex-
pression ratio of approximately 1 : 1 between wild-type
and modiﬁed gp64 protein (H¨ user et al [71]).
ELISA analysis indicated that the gp64 fusion proteins
were capable of binding to their speciﬁc ligands and that
the inserted coding region was located in an accessible
part of the gp64 protein loop (Ojala et al [70]). The CEA
fusion was incubated with PC-3 cells (previously shown
to express CEA) and the IgG binding domain express-
ing baculovirus was bound to cells by preincubation of
BHK cells with an anti-α5β1 integrin polyclonal antibody
and subsequent addition of the virus. Both methods re-
sult in detection of greater numbers of baculovirus par-
ticles bound to the cell surface as detected using an anti-
body against gp64. However, this increase in binding did
notappeartoenhancetransductionofthecellsasassessed
by EGFP transgene expression, by both ﬂuorescence mi-
croscopy and FACS (Ojala et al [70]). Thus the modiﬁ-
cation of the gp64 protein could be compromising nor-
mal functions such as endosomal escape. Thus if the rate-
determining stepoftransductionisendosomal escape,in-
creasing the number of bound viral particles would only
have a limited eﬀect on transduction eﬃciency. However,
this result is still very important for gene therapy, since
viral targeting could be utilised to reduce the number of
viral particles required for a gene therapy regime in vivo;
if the viruses can be engineered to bind more eﬃciently to
a speciﬁc cell type (eg, prostate cancer cells) than to other
cell types.
This is particularly relevant for liver, to where most
intravenously injected virus will locate, as judged by stud-
ies with adenoviruses (Mizuguchi and Hayakawa [72]).
By achieving retargeting, and by eliminating the liver cell
trophism, the number of particles required to be admin-
istered systemically would be reduced to the beneﬁt of
the patient (and also co-incidentally increasing cost ef-
fectiveness). To date, there are no publications that as-
sess whether a low MOI of targeted virus can achieve the
same level of transduction as a nontargeted virus at a high
MOI.
If the rate-limiting step of transduction is endosome
escape, then modiﬁcation of the baculoviral vector to me-
diate endosome lysis should further increase transduc-
tioneﬃciency.Toovercomethisblock,thevesicularstom-
atitis virus G protein (VSVG) has been used. For exam-
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transgenefromarecombinantbaculovirusinmammalian
cells is increased by up to 200 fold by incorporation of
VSVG on the virus surface (Barsoum et al [50]; Pieroni et
al[45]).VSVGmediatesescapefromendosomesbymem-
branefusion(Eidelmanetal[73]) but may also play a role
in binding and entry of the baculovirus into mammalian
cells (Tani et al [47]). Cell lines that are less permissive
for baculovirus transduction, such as HeLa, A549, CHO,
and NIH 3T3 cells, show the greatest diﬀerence in trans-
gene expression between the nonpseudotyped and VSVG-
expressing viruses, but even susceptible HepG2 cells show
a 10-fold-increase in transgene expression (Barsoum et
al[50]).Importantly,baculovirus-mediatedtransgeneex-
pression in HeLa cells, which are not very susceptible to
baculovirus transduction, can be seen at an MOI of 1
with the VSVG-pseudotyped virus compared to an MOI
of 100 with the nonpseudotyped virus (Barsoum et al
[50]).
In vivo, VSVG pseudotyping may confer protec-
tion from the complement response since the transduc-
tion eﬃciency of mouse skeletal muscle cells was 5–10
times greater than transduction with nonpseudotyped
virus. This improvement cannot be fully attributed to
the enhanced transport into the cells, as the VSVG-
pseudotyped virus only transduced twice as eﬃciently as
a nonpseudotyped virus in complement deﬁcient animals
(Pieroni et al [45]). Furthermore, VSVG-pseudotyped
retroviruses have been shown to be more resistant to
complementthannonpseudotypedretroviruses(Oryetal
[74]).
However, VSVG pseudotyping could compromise tar-
geting strategies, since VSVG has also previously been
shown to complement several functions of gp64 in a gp64
null baculovirus (Mangor et al [75]). In addition to medi-
ating endosome escape, VSVG-enhances entry into mam-
malian cells, since competition with an anti-gp64 anti-
body did not completely inhibit cell transduction with
a VSVG-pseudotyped virus. A non-VSVG-pseudotyped
virus was inhibited to the normal extent (Tani et al
[47]).
IMMUNE RESPONSES TO BACULOVIRUS
VECTORS IN VIVO
The earliest attempts to achieve baculoviral-mediated
gene transfer in vivo failed because of vector inactivation
by serum components, most probably those involved in
thecomplementresponse(Sandigetal[39]).Thecomple-
ment response is however also activated by other agents
used for gene delivery such as liposomes (Szebeni [76])
and synthetic DNA complexes (Plank et al [77]). Al-
though there is no preexisting humoral or cell mediated
memory against Bv in humans and other mammals, re-
peated administration does give rise to neutralising an-
tibodies. However, transgene expression has been shown
to persist in the absence of complement (Pieroni et al
[45]).
COMPLEMENT MANIPULATION TO POTENTIATE
Bv TRANSDUCTION IN VIVO
Activationofthecomplementresponsefollowingbac-
uloviral infection has been investigated in more detail and
it appears that complement is being activated via the clas-
sical pathway since serum depletion of C1q, unique to
the classical pathway, allowed complete survival of the
baculoviral vectors in vitro (Hofmann and Strauss [78]).
Hofmann and Strauss (Hofmann and Strauss [78]) ex-
plored various strategies for complement inhibition to
promote baculoviral vector survival in vivo. Incubation
of human serum with an antibody against complement
component C5, involved in both classical and alternative
pathways, promoted vector survival in a dose dependent
mannerinvitro(HofmannandStrauss[78]).Inaddition,
treatment of human blood and plasma with cobra venom
factor (CVF), an inhibitor of the complement compo-
nent C3, also resulted in almost complete survival of bac-
ulovirus vectors as opposed to the 1% that survived in the
absence of this factor (Hofmann and Strauss [78]). CVF
has successfully been used to deplete the complement re-
sponse in mammals in vivo, including monkeys (Chen et
al [79]).
A recombinant soluble complement receptor type 1
(sCR1) lacking transmembrane and cytoplasmic domains
has been shown to inhibit both classical and alternative
pathways of complement activation. Presence of this fac-
tor promoted baculoviral vector survival following incu-
bation with human serum and subsequent transduction
of Huh7 cells was approximately 5times more eﬃcient
than with baculoviruses incubated with serum in the ab-
sence of sCR1 (Hofmann et al [80]).
A further strategy designed to inhibit complement ac-
tivation by baculoviruses has been to engineer expression
of decay accelerating factor (DAF), a naturally occurring
negative regulator of both classical and alternative com-
plement pathways, on the virus surface as a fusion pro-
tein with gp64 (H¨ user et al [71]). Following incubation
with human serum, the DAF modiﬁed baculoviruses were
shown to be able to transduce Huh7 cells in the pres-
ence of complement at a much higher frequency than un-
modiﬁed viruses. This was shown to be due to increased
survival of the vectors in the presence of complement
(H¨ user et al [71]). The same vectors were injected into
rat livers in vivo and transgene expression, measured af-
ter 3days, was ﬁve times higher in the livers treated with
DAF-modiﬁed baculoviruses than the unmodiﬁed form
(H¨ user et al [71]).
Thus for cancer gene therapy, the complement re-
sponse against Bv can be overcome by short term bio-
chemical manipulation during viral inoculation. The op-
timal conditions have not been determined however,
and a number of alternative inhibition systems, to those
employed above can still be developed, particularly for
prostate cancer patients. In the brain however, the com-
plement response has no eﬀect on Bv gene transduc-
tion, and it has been proposed as a safe and eﬀective88 Lindsay Stanbridge et al 2003:2 (2003)
agent (Sarkis et al [40]) for treatment of neural disor-
ders.
CONCLUSIONS
Thus baculoviruses are a novel and sophisticated vec-
tor to carry therapeutic genes into human prostate can-
cers. They can be readily manipulated, using established
and now commercially available technology, and perhaps
most importantly, they have a vast capacity for exoge-
nous DNA. This will allow larger control sequences, and
even genes for transcriptional control proteins, which
will oﬀer greater independence from intracellular factors
(which could simply be turned oﬀ,f o re x a m p l e ,b y
genome CpG methylation, as a defence mechanism) and
provide greater control and speciﬁcity. The ability to tar-
get speciﬁc cell subtypes has been adequately demon-
strated,althoughdeﬁnitivedataforprostateremainstobe
conﬁrmed. The absence of preexisting humoral and cell-
mediated immune memory against nonhuman viruses is
well established, and if the complement inactivation can
beovercome,theireﬃciencyshouldexceedthatofhuman
viruses.
They are not without other serious problems, as in-
dustrial scale culture can be compounded by aggregation,
although in our experience when employed for protein
production, good virological practice prevents the build
up of defective interfering particles. There is also the rel-
atively high aﬃnity of Bv for liver cells, which could pro-
duce undesirable hepatic side eﬀects, unless other forms
of targeting (eg, transcriptional/therapeutic gene target-
ing) have been included in the ﬁnal vector construct. Re-
peatedBvinoculationwillundoubtedlyelicitapotentim-
mune response, but use of Bv in combination with other
viral (or nonviral) agents, could conceivably keep therapy
ahead of the defence mechanisms of both the patient and
his tumour, which have rendered prostate tumours so re-
calcitrant to normal anticancer therapy.
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